A Phase 1b, Multi-Centre, Parallel Group, Single Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Plague Vaccine (rF1 and rV Antigens) in Healthy Subjects

NCT00246467 Phase 1 COMPLETED

One hundred and five subjects will be recruited into three groups. Each subject will receive two doses of recombinant plague vaccine at one of three dose levels (rF1 and rV recombinant antigen proteins).

Details

Lead sponsor	PharmAthene UK Limited
Phase	Phase 1
Status	COMPLETED
Enrolment	123
Start date	2005-10
Completion	2007-04

Conditions

• Plague

Interventions

• Alhydrogel
• rF1 and rV protein antigens

Primary outcomes

• Safety of recombinant plague vaccine

Countries

United States, United Kingdom